Oculis Holding AG

XNAS:OCS

10.14

+0.16 (+1.60%)

7:52:55 PM EDT: $10.00 -0.14 (-1.38%)

Market Cap (Intraday)	588.97M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.27 Million
Adjusted EPS	-$0.49

See more estimates

10-Day MA	$10.71
50-Day MA	$12.06
200-Day MA	$20.66

See more pivots

Oculis Holding AG Stock, XNAS:OCS

Bahnhofstrasse 7, Bat D 3e Route J-D. Colladon, Zug, Zug 6300

Switzerland

Phone: +41.58.810.01.82

Number of Employees: 49

http://oculis.com

Description

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.